Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Gu
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall St set for lower open as AI jitters rekindle, oil gains
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- JPMorgan says AI stock selling may be nearing its limit as positioning resets
| (NASDAQ: NTRA) | Delayed: 413.38 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $413.38 | 52 Week High | $13.80 | |||
| Open | $413.38 | 52 Week Low | $6.52 | |||
| Day High | $413.38 | P/E | N/A | |||
| Day Low | $413.38 | EPS | $0.00 | |||
| Volume | 2,966 | |||||
